Advances in Lung Cancer Treatment Using Nanomedicines
- PMID: 36643475
- PMCID: PMC9835549
- DOI: 10.1021/acsomega.2c04078
Advances in Lung Cancer Treatment Using Nanomedicines
Abstract
Carcinoma of the lungs is among the most menacing forms of malignancy and has a poor prognosis, with a low overall survival rate due to delayed detection and ineffectiveness of conventional therapy. Therefore, drug delivery strategies that may overcome undesired damage to healthy cells, boost therapeutic efficacy, and act as imaging tools are currently gaining much attention. Advances in material science have resulted in unique nanoscale-based theranostic agents, which provide renewed hope for patients suffering from lung cancer. Nanotechnology has vastly modified and upgraded the existing techniques, focusing primarily on increasing bioavailability and stability of anti-cancer drugs. Nanocarrier-based imaging systems as theranostic tools in the treatment of lung carcinoma have proven to possess considerable benefits, such as early detection and targeted therapeutic delivery for effectively treating lung cancer. Several variants of nano-drug delivery agents have been successfully studied for therapeutic applications, such as liposomes, dendrimers, polymeric nanoparticles, nanoemulsions, carbon nanotubes, gold nanoparticles, magnetic nanoparticles, solid lipid nanoparticles, hydrogels, and micelles. In this Review, we present a comprehensive outline on the various types of overexpressed receptors in lung cancer, as well as the various targeting approaches of nanoparticles.
© 2022 The Authors. Published by American Chemical Society.
Conflict of interest statement
The authors declare no competing financial interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9835549/bin/ao2c04078_0001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9835549/bin/ao2c04078_0002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9835549/bin/ao2c04078_0003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9835549/bin/ao2c04078_0004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9835549/bin/ao2c04078_0005.gif)
![Scheme 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9835549/bin/ao2c04078_0011.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9835549/bin/ao2c04078_0006.gif)
![Scheme 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9835549/bin/ao2c04078_0012.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9835549/bin/ao2c04078_0007.gif)
![Figure 8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9835549/bin/ao2c04078_0008.gif)
![Scheme 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9835549/bin/ao2c04078_0013.gif)
![Figure 9](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9835549/bin/ao2c04078_0009.gif)
![Figure 10](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9835549/bin/ao2c04078_0010.gif)
Similar articles
-
Phytofabricated Nanoparticle Formulation for Cancer Treatment: A Comprehensive Review.Curr Drug Metab. 2022;23(10):818-826. doi: 10.2174/1389200223666220427101427. Curr Drug Metab. 2022. PMID: 35490313 Review.
-
Emerging trends in the novel drug delivery approaches for the treatment of lung cancer.Chem Biol Interact. 2019 Aug 25;309:108720. doi: 10.1016/j.cbi.2019.06.033. Epub 2019 Jun 18. Chem Biol Interact. 2019. PMID: 31226287 Review.
-
Nanotechnology: an evidence-based analysis.Ont Health Technol Assess Ser. 2006;6(19):1-43. Epub 2006 Nov 1. Ont Health Technol Assess Ser. 2006. PMID: 23074489 Free PMC article.
-
Trends in Nanomedicines for Cancer Treatment.Curr Pharm Des. 2020;26(29):3579-3600. doi: 10.2174/1381612826666200318145349. Curr Pharm Des. 2020. PMID: 32186271
-
Recent Advances of Nanotechnology in the Diagnosis and Therapy of Triple- Negative Breast Cancer (TNBC).Curr Pharm Biotechnol. 2022;23(13):1581-1595. doi: 10.2174/1389201023666211230113658. Curr Pharm Biotechnol. 2022. PMID: 34967294 Review.
Cited by
-
Enhancing hair regeneration: Recent progress in tailoring nanostructured lipid carriers through surface modification strategies.ADMET DMPK. 2024 Jul 20;12(3):431-462. doi: 10.5599/admet.2376. eCollection 2024. ADMET DMPK. 2024. PMID: 39091900 Free PMC article. Review.
-
Chia seed-mediated fabrication of ZnO/Ag/Ag2O nanocomposites: structural, antioxidant, anticancer, and wound healing studies.Front Chem. 2024 Jul 11;12:1405385. doi: 10.3389/fchem.2024.1405385. eCollection 2024. Front Chem. 2024. PMID: 39055045 Free PMC article.
-
Cutting-Edge Therapies for Lung Cancer.Cells. 2024 Mar 1;13(5):436. doi: 10.3390/cells13050436. Cells. 2024. PMID: 38474400 Free PMC article. Review.
-
Key Fabrications of Chitosan Nanoparticles for Effective Drug Delivery Using Flow Chemistry Reactors.Int J Nanomedicine. 2023 Dec 21;18:7889-7900. doi: 10.2147/IJN.S433756. eCollection 2023. Int J Nanomedicine. 2023. PMID: 38146468 Free PMC article.
-
Recent advancement of nanomedicine-based targeted delivery for cervical cancer treatment.Med Oncol. 2023 Nov 6;40(12):347. doi: 10.1007/s12032-023-02195-3. Med Oncol. 2023. PMID: 37930458 Review.
References
-
- Kumar S.; Sharma A. K.; Lalhlenmawia H.; Kumar D. Natural Compounds Targeting Major Signaling Pathways in Lung Cancer. Targeting Cellular Signalling Pathways in Lung Diseases 2021, 821–846. 10.1007/978-981-33-6827-9_37. - DOI
Publication types
LinkOut - more resources
Full Text Sources